Fibroblast-expressed LRRC15 is a receptor for SARS-CoV-2 spike and controls antiviral and antifibrotic transcriptional programs

PLoS Biol. 2023 Feb 9;21(2):e3001967. doi: 10.1371/journal.pbio.3001967. eCollection 2023 Feb.

Abstract

Although ACE2 is the primary receptor for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection, a systematic assessment of host factors that regulate binding to SARS-CoV-2 spike protein has not been described. Here, we use whole-genome CRISPR activation to identify host factors controlling cellular interactions with SARS-CoV-2. Our top hit was a TLR-related cell surface receptor called leucine-rich repeat-containing protein 15 (LRRC15). LRRC15 expression was sufficient to promote SARS-CoV-2 spike binding where they form a cell surface complex. LRRC15 mRNA is expressed in human collagen-producing lung myofibroblasts and LRRC15 protein is induced in severe Coronavirus Disease 2019 (COVID-19) infection where it can be found lining the airways. Mechanistically, LRRC15 does not itself support SARS-CoV-2 infection, but fibroblasts expressing LRRC15 can suppress both pseudotyped and authentic SARS-CoV-2 infection in trans. Moreover, LRRC15 expression in fibroblasts suppresses collagen production and promotes expression of IFIT, OAS, and MX-family antiviral factors. Overall, LRRC15 is a novel SARS-CoV-2 spike-binding receptor that can help control viral load and regulate antiviral and antifibrotic transcriptional programs in the context of COVID-19 infection.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Angiotensin-Converting Enzyme 2 / metabolism
  • Antiviral Agents / pharmacology
  • COVID-19* / genetics
  • Fibroblasts / metabolism
  • Humans
  • Membrane Proteins / genetics
  • Membrane Proteins / metabolism
  • Protein Binding
  • SARS-CoV-2* / metabolism

Substances

  • spike protein, SARS-CoV-2
  • Antiviral Agents
  • Angiotensin-Converting Enzyme 2
  • LRRC15 protein, human
  • Membrane Proteins

Grants and funding

This work was supported by the National Health and Medical Research Council (APP1107514, APP1158164, APP1158165 to G.G.N), University of Sydney (Drug Discovery Initiatve Seed Funding and Dr John and Anne Chong Fellowship to L.L.), Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (PP00P3_157448 to L.F., P400PM_194473 to O.H.A.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.